Mehalick David 4
4 · Coeptis Therapeutics Holdings, Inc. · Filed Mar 6, 2025
Insider Transaction Report
Form 4
Mehalick David
DirectorCEO and President10% Owner
Transactions
- Award
Non-Qualified Stock Options (right to buy)
2025-03-04+28,875→ 200,125 totalExercise: $10.56→ Common Stock (28,875 underlying)
Footnotes (4)
- [F1]On March 4, 2025, the reporting person received a grant of 28,875 non-qualified stock options, under the 2022 equity incentive plan.
- [F2]The exercise price is the FMV of the shares, which is equal to the Company's stock price on the Nasdaq Capital Market on the day of grant.
- [F3]Options will vest over 4 years, in equal quarterly installments over such period, with the final options vesting on 12/31/28.
- [F4]Expiration date is ten years from the day of grant.